Lundbeck has said it won't raise its offer to buy Avadel Pharma any further, clearing the way for the sleep disorder specialist to complete a merger with Alkermes. In a statement, Denmark-based ...
There are a variety of medications available to treat depression, the most popular being selective serotonin re-uptake inhibitors (SSRIs) such as Prozac, Zoloft and Paxil. While effective, these and ...
Approval granted by South Korea's Ministry of Food and Drug Safety (MFDS)Eptinezumab is an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody for the preventive treatment of migraine ...
Lundbeck just officially welcomed former CEO of Millennium, Deborah Dunsire, as its own chief in September. And as some might expect with a new leader, the central nervous system specialist is now ...
Trying to decide whether to jump into H. Lundbeck stock right now? You are not alone. With the share price closing at 44.92 and making strong upward moves of 3.9% this past week and 12.6% over the ...
Alkermes has been forced to raise its offer for narcolepsy drug developer Avadel Pharma, after a rival bid from Lundbeck was deemed superior. Dublin-domiciled Alkermes said today that it now has a new ...
Lundbeck has completed the acquisition of all outstanding shares of Longboard Pharmaceuticals, to bolster its capabilities in the neuro-rare disease sector. The transaction, worth approximately $2.6bn ...
VALBY, Denmark, May 6, 2025 /PRNewswire/ -- H. Lundbeck A/S is pleased to announce its agreement with the Danish Centre for AI Innovation (DCAI), the company established to run and operate Gefion, ...
After seeing its business take a beating over the last year, Teva Pharmaceutical’s board knew the drugmaker badly needed a permanent CEO. The search team was well aware of that fact and lured Lundbeck ...
Depression continues to be an area of major medical need. A number of effective and well known antidepressants exist, including Prozac (Lilly) and Zoloft (Pfizer). These drugs, now available in ...
Lundbeck announced this week that it will acquire Longboard Pharmaceuticals in a $2.6 billion deal, picking up the epilepsy drug bexicaserin in the process. The move — the largest to date for the ...
(Reuters) - Two remaining late-stage clinical trials testing an experimental Alzheimer's drug from Denmark's Lundbeck have failed, scuppering hopes for the medicine and underscoring the difficulty of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results